1-3 of 3
Stephan Oehen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation

Free
Marcos de Lima, Gabriela Sanchez-Petitto, Edmund Waller, Charles Craddock, Maria Calbacho, Giancarlo Fatobene, Daniel Ghali, Jennifer Rubel, Stephan Oehen, Jens Hasskarl
Journal: Blood
Blood (2025) 146 (Supplement 1): 6086.
https://doi.org/10.1182/blood-2025-6086
Published: 2025
Journal Articles

MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Free
Gabriela Sanchez-Petitto, Maria Calbacho, Agata Wieczorkiewicz-Kabut, Malika Souquieres, Julien Cachat, Imene Henaoui, Daniel Ghali, Cristina Fernandez, Jeff Steinberg, Stephan Oehen, Christos Stylianou, Elisabeth Kueenburg, Marcos de Lima
Journal: Blood
Blood (2024) 144 (Supplement 1): 4952.1.
https://doi.org/10.1182/blood-2024-203080
Published: 2024
Journal Articles

Clinical Assessment of Mocravimod As a Victim of Drug-Drug Interactions Via CYP3A Metabolism and Transporters

Free
Dymphy Huntjens, Stephan Oehen, Elisabeth Kueenburg
Journal: Blood
Blood (2024) 144 (Supplement 1): 5774.
https://doi.org/10.1182/blood-2024-193899
Published: 2024